Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information
Date:
Thursday, May 8, 2025
Time:
5:00 PM Eastern Time
United States:
1-800-717-1738
International:
1-646-307-1865
Conference ID:
90743
Webcast:
Link
About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara's lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com
MEDIA CONTACT:Michael FitzhughLifeSci Communicationsmfitzhugh@lifescicomms.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension
NORCROSS, Ga., June 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced that it will host a virtual key opinion leader (KOL) event on Monday, June 16, 2025 at 12:00 PM ET. To register, click here. The event will focus on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include: Naga P. Chalasani, MD, Professor of Gastroenterology and Hepatology, Adjunct Professor of Anatomy, Cell Biology and Physiology, & Director of Terance Kahn Liver Research Program, Indiana University School of Medicine; and Naim Alkhouri, MD, FAASLD, DABOM, Chief Academic Officer, Summit Clinical Research, & Director of the Steatotic Liver Program, North Shore Gastroenterology, Cleveland, OH. The event will highlight results from Galectin's NAVIGATE Phase 3 clinical trial evaluating belapectin for the treatment of MASH cirrhosis and portal. Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis. With no approved therapies to prevent or treat varices in MASH cirrhosis, belapectin may represent the first potential treatment to address this significant unmet need. A live question and answer session will follow the formal presentations. About Naga P. Chalasani, MD Naga P. Chalasani, MD completed medical school in India before he moved to the US to pursue Internal Medicine residency at Emory University in Atlanta, followed by a fellowship in Gastroenterology and Hepatology at the same institution. He joined IU in 1997 as an Assistant Professor in the Division of Gastroenterology and Hepatology. Dr. Chalasani is currently David W. Crabb Professor of Gastroenterology and Hepatology and Adjunct Professor of Anatomy, Cell Biology & Physiology and as Director of Terance Kahn Liver Research Program at Indiana University School of Medicine. He previously served as the GI Division Chief (2007-2020), Associate Dean for Clinical Research (2017-2020) interim Chair of the Department of Medicine (2020-2021) and Vice President for Academic Affairs at Indiana University Health (2022-2024). He is a highly regarded clinician and ranked as Top Doctor continuously for over 15 years. He has been continuously funded by the National Institutes of Health (NIH) since 1999 and is currently the PI on several U01 and R01 awards from the NIH. Dr. Chalasani is considered an authority in the fields of Non-Alcoholic Fatty Liver Disease (NAFLD) and Drug Induced Liver Injury (DILI), two highly significant public health problems. He is one of the most published and most cited investigators at Indiana University, with Google Scholar H-Index 120 and 75,000 citations (as of Feb 2025). He is an elected member of the American Society of Clinical Investigation (ASCI), the American Association of Physicians (AAP) and the National Academy of Medical Sciences – India (2024). He has mentored over 75 undergraduate and graduate students, medical students, sub-specialty trainees, and junior faculty. Twenty of his mentees are recipients of federal funding (K award, U01, R21, R01, DOD, and VA Merit Review). To honor his contributions and mentorship, Naga P Chalasani Endowed Professor in Gastroenterology and Hepatology has been established at Indiana University School of Medicine in October 2022. About Naim Alkhouri, MD, FAASLD, DABOM Naim Alkhouri, MD, FAASLD, DABOM is the Chief Academic Officer at Summit Clinical Research and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland, OH. Prior to joining Summit, Dr. Alkhouri served as the Chief Medical Officer and Director of the Steatotic Liver Disease program at Arizona Liver Health in Phoenix, AZ. Dr. Alkhouri is a key opinion leader in the field of MASH therapeutics and an advisor/ consultant to many pharmaceutical and biomarker development companies. He is Principal Investigator on several multicenter global MASH trials and a member of the AASLD MASLD Special Interest Group (MASLD SIG). Dr. Alkhouri has been published in over 260 publications to include publications in the New England Journal of Medicine, Lancet, JAMA, Nature Medicine, Gastroenterology, Hepatology, and Journal of Hepatology. He presents his work at both national and international medical conferences. About Galectin Therapeutics Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as 'may,' 'estimate,' 'could,' 'expect', 'look forward', 'believe', 'hope' and others. They are based on management's current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin's development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, full analysis of the NAVIGATE trial data may not product positive data; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company's current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin's drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin's business, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements. Company Contact:Jack Callicutt, Chief Financial Officer(678) 620-3186ir@ Investor Relations Contact:Kevin Gardnerkgardner@ Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics' galectin-3 inhibitor belapectin.
Yahoo
22 minutes ago
- Yahoo
Apple Rolls Out AI-Driven iOS 26 at WWDC
Apple (NASDAQ:AAPL) kicks off its AI and design revolution with iOS 26, unveiling a Liquid Glass interface and deeper ChatGPT integrations across core apps at WWDC 2025. Apple's vice president of Human Interface Design, Alan Dye, described iOS 26 as the broadest update ever, featuring Liquid Glassa dynamic material that marries glass-like optics with fluid responsivenessapplied universally to iPhone, iPad, Watch, TV and Mac. Native apps from Camera and Safari to Messages and Wallet get fresh layouts that adapt to context, while CarPlay and Maps gain streamlined controls. On the AI front, Apple amplifies its partnership with OpenAI by embedding ChatGPT into Image Playground and Genmoji, letting users generate bespoke images and emojis from text or photoswith full user consent. Visual Intelligence now lets you ask ChatGPT about anything on your screen without switching apps, and Live Translations delivers real-time captions and translations in Messages, FaceTime and Phoneeven with non-iPhone users. Craig Federighi, SVP of Software Engineering, announced expanded Siri personalization and an open Foundation Models Framework that enables any third-party app to tap into Apple Intelligence. Why It Matters: iOS 26's Liquid Glass aesthetic and deep AI mash-up could drive device upgrade cycles and boost services revenue as Apple rolls out paid AI features. It underscores Apple's strategy to monetize AI through its hardware moat rather than by chasing model supremacy. This article first appeared on GuruFocus.
Yahoo
25 minutes ago
- Yahoo
BlackSky Newest Gen-3 Delivers First Very High-Resolution Imagery at Warfighting Speed, 12 Hours Following Launch
Recently collected Gen-3 unit two images have demonstrated the timely operational value of space-based dynamic monitoring in support of strategic and tactical defense and intelligence missions HERNDON, Va., June 10, 2025--(BUSINESS WIRE)--BlackSky Technology Inc. (NYSE: BKSY) has delivered the first very high-resolution images from the company's second Gen-3 satellite just 12 hours following its successful launch last Monday. "In today's national security environment, BlackSky's customers require space-based intelligence that moves at warfighter speed," said Brian O'Toole, BlackSky CEO. "BlackSky's newest Gen-3 satellite has delivered low-latency, very high-resolution imagery on its first day in orbit demonstrating the maturity of our AI-enabled architecture and demonstrates the agile, mission-ready resilience of our commercial capabilities today." Early morning Gen-3, unit two, imagery collected yesterday at 7:45 a.m. China Standard Time over Golmud Air Base, Qinghai Province, China has demonstrated the timely operational value of high-cadence, space-based dynamic monitoring capabilities in support of strategic and tactical surveillance, reconnaissance and tracking defense and intelligence missions. Gen-3 gives decision makers the ability to discern vital aircraft movements, ground vehicle positioning and critical facility operations that can provide valuable real-time context to multisource intelligence efforts. "BlackSky is committed to giving customers an unparalleled operational advantage at disruptive speed, scale and economics. Our real-time dynamic monitoring capabilities offer a strong complement to national space assets, especially in support of time-dominant strategic and tactical operations," said O'Toole. As part of BlackSky's high-cadence, time-diverse constellation, each new Gen-3 satellite is expected to accelerate the development of new customer applications in automated real-time and predictive battlefield monitoring. Gen-3 customers have subscription-based access to high-cadence, time diverse 35-centimeter very high-resolution imagery with AI-enabled automated detection analytics that identify and classify a wide library of vehicles, aircraft, vessels and other objects of military interest. As BlackSky's constellation evolves with the regular addition of Gen-3 satellites, BlackSky will continue to optimize for increased constellation capacity and flexibility giving customers confidence in reliable access to services. About BlackSky BlackSky is a real-time, space-based intelligence company that delivers on-demand, high frequency imagery, analytics, and high-frequency monitoring of the most critical and strategic locations, economic assets, and events in the world. BlackSky owns and operates one of the industry's most advanced, purpose-built commercial, real-time intelligence systems that combines the power of the BlackSky Spectra® tasking and analytics software platform and our proprietary low earth orbit satellite constellation. With BlackSky, customers can see, understand and anticipate changes for a decisive strategic advantage at the tactical edge, and act not just fast, but first. BlackSky is trusted by some of the most demanding U.S. and international government agencies, commercial businesses, and organizations around the world. BlackSky is headquartered in Herndon, VA, and is publicly traded on the New York Stock Exchange as BKSY. To learn more, visit and follow us on X. Forward-Looking Statements Certain statements in this press release may contain forward-looking statements within the meaning of the federal securities laws with respect to BlackSky. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. In addition, forward-looking statements reflect our expectations, plans, or forecasts of future events and views as of the date of this communication. We anticipate that subsequent events and developments will cause their assessments to change. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Additional risks and uncertainties are identified and discussed in BlackSky's disclosure materials filed from time to time with the SEC which are available at the SEC's website at or on BlackSky's Investor Relations website at View source version on Contacts Investor Contact Aly BonillaVP, Investor Relationsabonilla@ Media Contact Pauly CabellonSr. Director, External Communicationsbksypr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
